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Abstract  
Introduction: The term anti-nuclear antibody (ANA) is used to define a large group of autoantibodies which specifically bind to nuclear elements. 
Although healthy individuals may also have ANA positivity, the measurement of ANA is generally used in the diagnosis of autoimmune disorders. 
However, various studies have shown that ANA testing may be overused, especially in pediatrics clinics. Our aim was to investigate the reasons for 
antinuclear antibody (ANA) testing in the general pediatrics and pediatric rheumatology clinics of our hospital and to determine whether ANA 
testing was ordered appropriately by evaluating chief complaints and the ultimate diagnoses of these cases. Methods: The medical records of 
pediatric patients in whom ANA testing was performed between January 2014 and June 2016 were retrospectively evaluated. Subjects were 
grouped according to the indication for ANA testing and ANA titers. Results: ANA tests were ordered in a total of 409 patients during the study 
period, with 113 positive ANA results. The ANA test was ordered mostly due to joint pain (50% of the study population). There was an increased 
likelihood of autoimmune rheumatic diseases (ARDs) with higher ANA titer. The positive predictive value of an ANA test was 16% for any 
connective tissue disease and 13% for lupus in the pediatric setting. Conclusion: in the current study, more than one-fourth of the subjects were 
found to have ANA positivity, while only 15% were ultimately diagnosed with ARDs. Our findings underline the importance of an increased 
awareness of correct indications for ANA testing. 
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Introduction 
 
The presentation of rheumatic diseases in children may be similar to 
the manifestations of various infections, malignancies and 
endocrinological disorders. Although laboratory tests have become 
pivotal in the differential diagnosis of rheumatic diseases, a test 
which can reliably confirm or exclude rheumatic diseases in children 
does not exist. In pediatric rheumatology, 80-85% of the data 
leading to a diagnosis is obtained via a comprehensive medical 
history. Therefore, obtaining a detailed medical history and 
meticulous evaluation of the data is of utmost importance in the 
rheumatology clinic. Medical history should be followed by an 
extensive physical examination and the clinician should have 
comprehensive knowledge about rheumatic diseases [1-4]. In 
addition to clinical evaluation, autoantibody measurements have 
become a powerful guide for diagnosis and may also provide 
important data in terms of prognosis, disease activity and treatment 
of rheumatic diseases. Autoantibody testing has been utilized for the 
diagnosis and treatment evaluation of autoimmune diseases for 
more than 50 years [5]. More specifically, antinuclear antibody 
(ANA) testing has become instrumental in the diagnosis of certain 
autoimmune rheumatic diseases (ARDs). Quantification of 
autoantibodies may suggest the presence of an autoimmune disease 
or inform the clinician about the severity of the disease and/or the 
immune response associated with the disease [6]. 
  
Antinuclear antibodies are a group of autoantibodies which can be 
detected in systemic autoimmune diseases such as systemic lupus 
erythematosus (SLE), Sjögren syndrome, systemic sclerosis, 
inflammatory myositis, mixed connective tissue diseases (MCTD) 
and rheumatoid arthritis (RA) [7]. However, in the pediatric clinical 
practice, ANA tests are commonly requested in patients with 
musculoskeletal complaints, most of which are not related to ARDs. 
When an ANA test is ordered without strong clinical suspicion for 
ARDs, there are two outcomes: the result is either negative-and 
rules out ARDs-or the test is positive, which leads to the 
requirement for detailed clinical examination and medical history of 
the patient (which should have been done prior to ANA testing). 
Ultimately, if the patient is not diagnosed with an ARD, then the test 
has only caused anxiety for the caretaker of the patient and has 
increased the number of referrals to pediatric rheumatology clinics. 
It is important to be aware of the fact that a negative ANA test 
result is more valuable than a positive one -as it rules out ARDs; 
however, ANA tests should only be ordered with sufficient clinical 
suspicion for ARDs. An incomplete understanding of when to 
request an ANA test and how to interpret the results may reduce 
patient and caretaker satisfaction and also cause a substantial 
burden to the healthcare system of a developing country. Thus, 
evaluating the indications for ANA testing and their results may 
prove beneficial for the pediatric rheumatology practice and the 
training of pediatrics residents. In this study, the ANA results of 
patients who were consulted to pediatric and pediatric rheumatology 
outpatient clinics with suspicion for autoimmune diseases were 
reviewed retrospectively. The relationships between chief 






In this retrospective single center study, which took place in the 
general pediatrics and pediatric rheumatology clinic of a university 
hospital, we reviewed the records of children in whom ANA testing 
was performed between January 2014 and June 2016. We excluded 
subjects in which clinical indications for ANA testing were not 
available. Subjects were grouped according to the indication for ANA 
testing and ANA titers. The age, gender, chief complaints, ANA test 
results and final diagnoses of patients were recorded by accessing 
their data from the hospital information system. The ANA tests were 
performed by the immunofluorescence technique in microbiology 
and immunology laboratories. Hep-2 cell lines were used for ANA 
testing. 
  
Statistical analysis: Data analysis was performed with the IBM 
SPSS v21 software for Windows (IBM Corp. Armonk, NY, USA). We 
presented categorical data with numbers and percentages and 
continuous data with means and standard deviations. For the 
comparison of groups, we used the chi square test for categorical 
variables and the Student's t test for continuous variables. We 





Antinuclear antibody testing was performed in a total of 409 
patients during the indicated study period. The age range of the 
study population was 5-18 years. We listed reasons for ANA testing 
requests and study outcomes in Table 1 and the association of ANA 
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titers with ultimate diagnoses in Table 2. Overall, 113 (%27.6) 
patients had positive ANA test results. ANA test was positive in 15 
(%13.2) SLE patients and 18 (%15.9) ARDs. The most common 
reason for requesting ANA testing was joint pain (50% of the study 
population). Most of the patients with ANA positivity and ARDs were 
female. Among ANA positive subjects, girls tended to have a higher 
rate of ARDs compared with boys, but the difference was not 
statistically significant (17.7% vs. 8.6%, p > 0.05). None of the 
patients with ANA titers less than 1:160 were diagnosed with ARDs, 
while subjects with titers > 1:160 had a similar rate of ARDs (p = 
0.2) (Table 3). The positive predictive value of an ANA test was 
16% for any connective tissue disease and 13% for SLE. Lupus 
patients who referred to the clinic with skin and joint symptoms 
were generally diagnosed as a result of further investigation. Among 
a total of 64 patients with mucocutaneous symptoms (signs or 
symptoms involving the hair, skin or oral mucosa), 28 were detected 
to be ANA positive and 8 of these ANA positive patients were 
diagnosed with Lupus. Although joint symptoms overlapped with 
mucocutaneous symptoms in some of the patients, they were 
evaluated according to their predominant symptom. Patients with 
joint symptoms constituted 50% of all requests for ANA testing. 
Although 47 of these patients were diagnosed with JIA and 6 with 
FMF, the remaining patients with joint symptoms did not 
demonstrate any specific signs for ARDs. The cause of joint 
symptoms were considered to be growth pain in many of the 
remaining subjects. In addition, it was determined that 11 of the 
patients with widespread pain had vitamin D deficiency. 
  
Among 50 JIA patients who were tested for ANA, 12 had positive 
results. Although ANA positivity is associated with uveitis according 
to the medical literature [8, 9], the evaluation of physical 
examination records showed that none of our patients had any 
significant sign of uveitis. Among 13 chronic ITP follow-up patients 
who had been tested, 5 patients had positive ANA results. Only one 
of these patients was found to have an ARD. This patient was 
diagnosed with Sjögren's syndrome in light of antibody test results 
which were requested with a preliminary diagnosis of autoimmune 
hepatitis due to liver enzyme elevation. Afterwards, further 
questioning revealed that the patient had had parotitis attacks 
which were not recognized by their family. A minor salivary gland 
biopsy was also consistent with Sjögren's syndrome. Fourteen 
patients were referred due to Raynaud's phenomenon and 3 were 
determined to be ANA positive of which one was diagnosed with 
Lupus. After the capillaroscopic evaluation of the patients who had 
ANA positive results, various non-ARD abnormalities were 
determined in 3 patients. Among 8 patients with various urinary 
system abnormalities such as hematuria and proteinuria, 2 had 
positive ANA results. However, none of these patients were 
diagnosed with ARDs with further analysis. One of these patients 
had been previously diagnosed with idiopathic nephrotic syndrome, 
but kidney biopsy was ordered due to resistance to corticosteroid 
treatment and ANA positivity. The biopsy confirmed lupus (full 
house pattern). Seven patients with recurrent infections were tested 
for ANA, 2 of them had positive results. None of these patients had 
an ultimate diagnosis of ARD. Among the 16 patients with 
constitutional symptoms, only one had ANA positivity. Two of the 16 
were diagnosed with FMF and 1 was diagnosed with Kawasaki 
Disease. Among 10 patients with recurrent abdominal pain, 3 were 





In pediatrics, unnecessary utilization of ANA testing is very common 
although the test's specificity and sensitivity are generally low for 
rheumatic and musculoskeletal system diseases. The ANA test is 
commonly ordered in patients with musculoskeletal symptoms which 
are, in most cases, not associated with ARDs. Likewise, the most 
common cause for requesting ANA in the current study was joint 
pain (50%). The likelihood of ANA positivity and ARDs tended to be 
higher in girls compared to boys. The rate of an ARD diagnosis after 
a positive ANA test was 15% in the current study, and most of 
these patients were diagnosed with SLE (overall rate: 13%). The 
overuse of ANA testing is a major problem worldwide. This is partly 
due to the nature of the test; with titers such as 1:160, the number 
of false positives are reduced to around 5%, but the possibility for 
false-negatives increase; the opposite is also true with titers such as 
1:40, at which almost 30% of the population are assumed to have a 
positive result [1-3, 10-13]. Some authors have suggested that 
positive results at 1:40 titer should be reported in order to identify 
as many ARD patients as possible [12]. However, this approach 
increases the number of false-positive results; thus, the clinician 
should order ANA tests only when there exists a strong suspicion for 
ARDs and therefore, may confirm or rule-out the diagnosis. A study 
by Malleson et al. showed that, in their center, 41% of ANA tests in 
children without rheumatic diseases had "positive" results at a titer 
of 1:20 [14]. This shows the importance of detailed physical 
examination and thorough medical history prior to ANA testing. 
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Antinuclear antibody testing should be used as a diagnostic test only 
when diagnoses of SLE, MCTD and overlap syndromes are 
considered. In children with signs and symptoms consistent with 
these ARDs, the ANA test result would almost always be positive 
[14]. The findings of our study also suggest that, when the signs 
and symptoms of patients causes the clinician to consider ARDs as 
probable diagnosis, positive ANA test results can be used to confirm 
diagnosis. Various studies show ANA positivity to be relatively 
frequent in the healthy population [14, 15]. Among children, 2-15% 
have positive ANA, especially with low titers [16, 17]. Therefore, 
ANA testing should not be used as a screening tool for ARDs in the 
pediatric setting. However, if it is requested and there is no sign of 
a systemic disease and the medical history and examination of the 
child does not suggest ARDs, then positive ANA results in low titers 
should be considered irrelevant. While ANA positivity has a very high 
sensitivity for SLE, MCTD and overlap syndromes (as high as 98%), 
its positive predictive value is very low (10%) [4, 18, 19]. Similar to 
the literature, we found the positive predictive value of ANA 
positivity as 13% for SLE in our study. Furthermore, none of the 
patients with titers lower than 1:160 had an ultimate diagnosis of 
ARDs. A positive ANA test may indicate the presence of an immune 
disfunction; however, this situation rarely causes a disease [20]. 
According to a study performed in a pediatric rheumatology clinic, 
only 55% of the subjects who had a positive ANA test had an 
inflammatory rheumatic disease [21]. This rate was relatively lower 
in our study (28%). However, this may be explained by the 
inclusion of data from the general pediatrics clinic in addition to the 
pediatric rheumatology clinic. According to a study in which the 
clinical use of ANA was investigated, Among 110 subjects with a 
positive ANA test, 10 had SLE, 18 had JIA, 1 had MCTD, and 
another patient had Raynaud phenomenon [20]. In our study, 113 
patients had positive ANA test results and the distribution of 
diagnoses were as follows: 15 SLE, 10 JIA, 3 Raynaud phenomenon, 
2 Sjogren's syndrome and 1 polymyositis. 
  
Besides the increase in referrals and economical loss caused by the 
overuse of ANA testing, false-positive results often lead to further 
follow-up testing, patient/caretaker anxiety, and even misdiagnoses 
and improper treatments. Narain et al [22], in their study comprised 
of 137 patients with a positive ANA test without a systemic illness, 
found that 39 had been treated with prednisone at doses as high as 
60 mg per day. Raynaud's phenomenon may develop secondarily to 
SLE, scleroderma and rheumatoid arthritis (RA) in 19% of the 
patients [23]. This probability increases to 30% if the ANA test is 
positive and decreases to 7% if the test is negative [24]. Among 
tthe 14 patients in our study who were referred to the clinic with 
Raynaud's phenomenon, 3 were determined to be positive for ANAs. 
In our study, 2 of the 8 patients with hematuria and proteinuria 
were tested positive for ANA. However, after further analysis, these 
patients were not diagnosed with any type of ARDs. One of the 
patients had been previously diagnosed with idiopathic nephrotic 
syndrome; however, after kidney biopsy-which was ordered due to 
resistance to corticosteroid treatment and ANA positivity- the patient 
turned out to have lupus (full house pattern). Another condition 
where a positive ANA test may be of some value in children is 
idiopathic thrombocytopenic purpura (ITP). In a study comprised of 
87 children with ITP, 36% of those with a positive ANA (titer ≥ 
1:40) were found to develop "autoimmune symptoms" [25]. In the 
current study, 5 of the 13 chronic ITP follow-up patients tested for 





More than one-fourth of the subjects included in the study were 
found to have ANA positivity, while only 15% were ultimately 
diagnosed with ARDs. We believe that ANA testing may be seen as 
a screening tool for ARDs by clinicans; while this approach may 
have merit when a patient has a medical history and examination 
findings consistent with SLE, MCTD and overlap syndrome, the 
sensitivity and specificity of the test is too low to be used as a 
screening test for other ARDs. In addition, false-positive results 
cause more harm than good for patients and clinicians. Thus, our 
findings underline the importance of an increased awareness of 
correct indications for ANA testing in pediatrics clinics. 
 
What is known about this topic 
 ANA positivity to be highly prevalent in both the general 
and various patient populations; 
 ANA tests are overused; 
 ANA test is highly specific for some ARDs, such as SLE 
and Sjögren syndrome, but not for others. 
What this study adds 
 No ANA-associated rheumatic disease was identified in 
patients with an ANA < 1:160; 
 According to the information obtained from this study, the 
ANA test was ordered unnecessarily in many cases; 
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 These results may be valuable in avoiding unnecessary 
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Table 1: Chief complaints of patients in whom antinuclear 
antibody tests were requested 
Chief Complaint 
Number of Patients 
n=409 (%) 
Musculoskeletal disorders (especially 
joint pain) 
207 (%50.6) 
Mucocutaneous symptoms (skin, oral 
and hair problems) 
64 (%15.7) 
Hematologic disorders 19 (%4.7) 
Constitutional symptoms 16 (%3.9) 
Abdominal pain 10 (%2.4) 
Raynaud's phenomenon 14 (%3.4) 
Abnormality in urine urinalysis 8 (%1.9) 
Recurrent infections 7 (%1.7) 
Other 64 (15.7) 
  
 









Age 10.5 10.1 0.8 
Sex 
   
Female 90 157 
< 0.001 
Male 23 139 
ARDs 18 0 < 0.001 
Female 16 0 < 0.001 
Male 2 0 < 0.001 
Lupus 15 0 
< 0.001 Polymyositis 1 0 
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Table 3: Antinuclear antibody (ANA) titers 
TITER n (%)   
1/80 13 (%11.5)   
1/160 34 (%30.0) 5 LUPUS, 5 JIA, 2 ITP, 1 PM 
1/320 30 (%26.5) 5 LUPUS, 1 SJOGREN, 2 ITP 
1/640 19 (%16.9) 2 LUPUS, 3 JIA, 1 ITP 
1/1280 16 (%14.2) 2 LUPUS, 2 JIA, 1 SJOGREN 
1/2560 1 (%0.9) 1 LUPUS 
TOTAL POSITIVE 113(%100)   
  
 
